Bone turnover across the menopause transition: Correlations with inhibins and follicle-stimulating hormone

Daniel S. Perrien, Sara J. Achenbach, Samuel E. Bledsoe, Brandon Walser, Larry J. Suva, Sundeep Khosla, Dana Gaddy

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Context: Longitudinal clinical studies demonstrate that increases in bone turnover that occur in perimenopausal women correlate better with elevated serum FSH than with changes in serum estradiol (E2). This perimenopausal rise in FSH is due to a selective decrease in ovarian inhibin B (InhB). Our previous demonstration that inhibins suppress both osteoblast and osteoclast development suggests that changes in serum inhibins may regulate osteoblast and osteoclast differentiation and thereby bone turnover, independent of changes in sex steroids. Objective: The objective of this study was to determine whether decreased serum inhibin A (InhA) and InhB levels correlate with increases in markers of bone turnover in women across the menopause transition and to evaluate serum inhibins as better predictors of bone turnover markers across the menopause transition than FSH or bioavailable E2. Design: We studied a cross-sectional age-stratified population sample of 188 pre- and postmenopausal women not using oral contraceptives or hormone replacement therapy (age, 21-85 yr). Results: Serum InhA and InhB levels significantly correlated inversely with markers of bone formation and bone resorption in pre- and perimenopausal women and with markers of bone formation in postmenopausal women (InhA only). FSH was not significantly correlated with bone turnover in either pre- or postmenopausal women; however, FSH was significantly correlated with bone resorption (C-terminal collagen I cross-link) in perimenopausal women (age, 45-54 yr). Using multivariate analyses, serum InhA better predicted bone formation and resorption markers in premenopausal women than either FSH or bioavailable E2. Conclusions: Decreases in inhibin levels across the menopause transition are associated with increasing bone turnover, regardless of changes in sex steroids or FSH.

Original languageEnglish (US)
Pages (from-to)1848-1854
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume91
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Inhibins
Bone Remodeling
Follicle Stimulating Hormone
Menopause
Bone
Serum
Bone Resorption
Osteogenesis
Osteoclasts
Osteoblasts
Steroids
Hormone Replacement Therapy
Oral Contraceptives
Longitudinal Studies
Estradiol
Collagen
Multivariate Analysis
Bone and Bones
inhibin A
Demonstrations

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Bone turnover across the menopause transition : Correlations with inhibins and follicle-stimulating hormone. / Perrien, Daniel S.; Achenbach, Sara J.; Bledsoe, Samuel E.; Walser, Brandon; Suva, Larry J.; Khosla, Sundeep; Gaddy, Dana.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 91, No. 5, 05.2006, p. 1848-1854.

Research output: Contribution to journalArticle

Perrien, Daniel S. ; Achenbach, Sara J. ; Bledsoe, Samuel E. ; Walser, Brandon ; Suva, Larry J. ; Khosla, Sundeep ; Gaddy, Dana. / Bone turnover across the menopause transition : Correlations with inhibins and follicle-stimulating hormone. In: Journal of Clinical Endocrinology and Metabolism. 2006 ; Vol. 91, No. 5. pp. 1848-1854.
@article{810017de60fd497bac76426326f1d8ae,
title = "Bone turnover across the menopause transition: Correlations with inhibins and follicle-stimulating hormone",
abstract = "Context: Longitudinal clinical studies demonstrate that increases in bone turnover that occur in perimenopausal women correlate better with elevated serum FSH than with changes in serum estradiol (E2). This perimenopausal rise in FSH is due to a selective decrease in ovarian inhibin B (InhB). Our previous demonstration that inhibins suppress both osteoblast and osteoclast development suggests that changes in serum inhibins may regulate osteoblast and osteoclast differentiation and thereby bone turnover, independent of changes in sex steroids. Objective: The objective of this study was to determine whether decreased serum inhibin A (InhA) and InhB levels correlate with increases in markers of bone turnover in women across the menopause transition and to evaluate serum inhibins as better predictors of bone turnover markers across the menopause transition than FSH or bioavailable E2. Design: We studied a cross-sectional age-stratified population sample of 188 pre- and postmenopausal women not using oral contraceptives or hormone replacement therapy (age, 21-85 yr). Results: Serum InhA and InhB levels significantly correlated inversely with markers of bone formation and bone resorption in pre- and perimenopausal women and with markers of bone formation in postmenopausal women (InhA only). FSH was not significantly correlated with bone turnover in either pre- or postmenopausal women; however, FSH was significantly correlated with bone resorption (C-terminal collagen I cross-link) in perimenopausal women (age, 45-54 yr). Using multivariate analyses, serum InhA better predicted bone formation and resorption markers in premenopausal women than either FSH or bioavailable E2. Conclusions: Decreases in inhibin levels across the menopause transition are associated with increasing bone turnover, regardless of changes in sex steroids or FSH.",
author = "Perrien, {Daniel S.} and Achenbach, {Sara J.} and Bledsoe, {Samuel E.} and Brandon Walser and Suva, {Larry J.} and Sundeep Khosla and Dana Gaddy",
year = "2006",
month = "5",
doi = "10.1210/jc.2005-2423",
language = "English (US)",
volume = "91",
pages = "1848--1854",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Bone turnover across the menopause transition

T2 - Correlations with inhibins and follicle-stimulating hormone

AU - Perrien, Daniel S.

AU - Achenbach, Sara J.

AU - Bledsoe, Samuel E.

AU - Walser, Brandon

AU - Suva, Larry J.

AU - Khosla, Sundeep

AU - Gaddy, Dana

PY - 2006/5

Y1 - 2006/5

N2 - Context: Longitudinal clinical studies demonstrate that increases in bone turnover that occur in perimenopausal women correlate better with elevated serum FSH than with changes in serum estradiol (E2). This perimenopausal rise in FSH is due to a selective decrease in ovarian inhibin B (InhB). Our previous demonstration that inhibins suppress both osteoblast and osteoclast development suggests that changes in serum inhibins may regulate osteoblast and osteoclast differentiation and thereby bone turnover, independent of changes in sex steroids. Objective: The objective of this study was to determine whether decreased serum inhibin A (InhA) and InhB levels correlate with increases in markers of bone turnover in women across the menopause transition and to evaluate serum inhibins as better predictors of bone turnover markers across the menopause transition than FSH or bioavailable E2. Design: We studied a cross-sectional age-stratified population sample of 188 pre- and postmenopausal women not using oral contraceptives or hormone replacement therapy (age, 21-85 yr). Results: Serum InhA and InhB levels significantly correlated inversely with markers of bone formation and bone resorption in pre- and perimenopausal women and with markers of bone formation in postmenopausal women (InhA only). FSH was not significantly correlated with bone turnover in either pre- or postmenopausal women; however, FSH was significantly correlated with bone resorption (C-terminal collagen I cross-link) in perimenopausal women (age, 45-54 yr). Using multivariate analyses, serum InhA better predicted bone formation and resorption markers in premenopausal women than either FSH or bioavailable E2. Conclusions: Decreases in inhibin levels across the menopause transition are associated with increasing bone turnover, regardless of changes in sex steroids or FSH.

AB - Context: Longitudinal clinical studies demonstrate that increases in bone turnover that occur in perimenopausal women correlate better with elevated serum FSH than with changes in serum estradiol (E2). This perimenopausal rise in FSH is due to a selective decrease in ovarian inhibin B (InhB). Our previous demonstration that inhibins suppress both osteoblast and osteoclast development suggests that changes in serum inhibins may regulate osteoblast and osteoclast differentiation and thereby bone turnover, independent of changes in sex steroids. Objective: The objective of this study was to determine whether decreased serum inhibin A (InhA) and InhB levels correlate with increases in markers of bone turnover in women across the menopause transition and to evaluate serum inhibins as better predictors of bone turnover markers across the menopause transition than FSH or bioavailable E2. Design: We studied a cross-sectional age-stratified population sample of 188 pre- and postmenopausal women not using oral contraceptives or hormone replacement therapy (age, 21-85 yr). Results: Serum InhA and InhB levels significantly correlated inversely with markers of bone formation and bone resorption in pre- and perimenopausal women and with markers of bone formation in postmenopausal women (InhA only). FSH was not significantly correlated with bone turnover in either pre- or postmenopausal women; however, FSH was significantly correlated with bone resorption (C-terminal collagen I cross-link) in perimenopausal women (age, 45-54 yr). Using multivariate analyses, serum InhA better predicted bone formation and resorption markers in premenopausal women than either FSH or bioavailable E2. Conclusions: Decreases in inhibin levels across the menopause transition are associated with increasing bone turnover, regardless of changes in sex steroids or FSH.

UR - http://www.scopus.com/inward/record.url?scp=33646429482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646429482&partnerID=8YFLogxK

U2 - 10.1210/jc.2005-2423

DO - 10.1210/jc.2005-2423

M3 - Article

C2 - 16449331

AN - SCOPUS:33646429482

VL - 91

SP - 1848

EP - 1854

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -